ABSTRACT
El hiperparatiroidismo primario es la principal causa de hipercalcemia en pacientes no hospitalizados, estando causado en el 85-90 % de los casos por un adenoma solitario. La cirugía radioguiada (CRG) es una técnica quirúrgica mínimamente invasiva que emplea medicamentos radiofármacos para facilitar la localización y extirpación de lesiones benignas o malignas. La cirugía radioguiada de paratiroides (CRGP), como técnica GOSTT (Guided intraOperative Scintigraphic Tumor Targeting) y mínimamente invasiva, precisa de una prueba de diagnóstico por la imagen que permita localizar anatómicamente la lesión y establecer su comportamiento funcional. El MIBI-99mTc es el trazador de elección, debiendo siempre incluir estudios tomográficos, especialmente la SPECT-CT. Se emplea durante la CRGP junto con sondas intraoperatorias, gammacámaras y dispositivos SPECT portátiles, herramientas de navegación y sistemas robóticos laparoscópicos. La CRGP disminuye el tiempo quirúrgico, los costes hospitalarios y la morbilidad sobre el paciente, con una elevada efectividad y eficiencia
Primary hyperparathyroidism is the main cause of hypercalcemia in outpatients. It is caused in 85-90 % of cases by a solitary adenoma. Radioguided surgery (RGS) is a minimally invasive surgical technique that uses radiopharmaceutical drugs to facilitate the location and removal of benign or malignant lesions. Radioguided parathyroid surgery (RGPS), as a GOSTT (Guided intraOperative Scintigraphic Tumor Targeting) technique and minimally invasive, requires a diagnostic imaging test to anatomically locate the lesion and establish its functional behavior. The MIBI-99mTc is the tracer of choice, and should always include tomographic studies, especially the SPECT-CT. This radiotracer is used during the RGPS together with intraoperative probes, gammacameras and portable SPECT devices, navigation tools and laparoscopic robotic systems. The RGPS reduces surgical time, hospital costs and patient morbidity with high effectiveness and efficiency
Subject(s)
Humans , Parathyroid Diseases/surgery , Parathyroid Glands/surgery , Surgery, Computer-Assisted , Parathyroid Neoplasms/surgery , Minimally Invasive Surgical Procedures , Radiopharmaceuticals , Radionuclide ImagingABSTRACT
AIMS: Temporary transfemoral cardiac pacing is widely accepted, but is associated with high incidence of asymptomatic deep vein thrombosis (DVT), which in turn is associated with restricted patient mobility. The passive-fixation lead typically used in this procedure restricts patient mobility during implantation. METHODS AND RESULTS: An active-fixation lead allowing normal ambulation was prospectively assessed in 47 consecutive patients. Prior to explantation, venous duplex ultrasound was performed to determine DVT incidence, with the contralateral leg as control. To reduce possible false negatives, ventilation/perfusion scintigraphy was also performed (n = 42). Patient mobility during implantation was classified as high (n = 29), moderate (n = 6), or low (n = 12). Anticoagulants were limited to cases meeting standard guidelines. Asymptomatic DVT was diagnosed in three patients (6.4%), compared with 25-39% reported using standard passive-fixation leads. Furthermore, all of these patients had low mobility during the implantation period. No post-implantation lung scan showed high probability of pulmonary embolism. CONCLUSION: In the 75% of patients with moderate or high mobility, there were no DVT cases. The 6.4% DVT incidence was limited to patients with low mobility and was significantly lower than the norm for this procedure. A larger, randomized study is needed to confirm the benefits of the mobility allowed by an active-fixation lead.
